Completed PHASE3 INTERVENTIONAL 3-arm NCT01711125

Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease (BacALD)

Exploring the Efficacy and Biobehavioural Basis of Baclofen in the Treatment of Alcoholic Liver Disease

Sponsor: National Health and Medical Research Council, Australia

Conditions Alcohol Dependence Alcoholic Liver Disease

Interventions Baclofen 30mg/day Baclofen 75mg/day Placebo

Updated 6 times since 2017 Last updated: Aug 7, 2017 Started: Mar 31, 2013 Primary completion: Jun 30, 2017 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Alcohol Dependence and Alcoholic Liver Disease and is currently completed. National Health and Medical Research Council, Australia leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Aug 2017 — Jun 2018 [monthly]

Completed PHASE3

Status: Unknown Status → Completed

▶ Show 1 earlier version

Jan 2017 — Aug 2017 [monthly]

Unknown Status PHASE3

First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Health and Medical Research Council, Australia
South West Sydney Local Health District
University of Sydney

Data source: South West Sydney Local Health District

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sydney, Australia